Conversion Therapy With Retlirafusp Alfa Plus Chemotherapy in Gastric or Gastroesophageal Junction Adenocarcinoma

NCT07709767 · clinicaltrials.gov ↗

PHASE2

Phase

NOT_YET_RECRUITING

Status

21

Enrollment

OTHER

Sponsor class

Conditions

Gastric Adenocarcinoma
Gastroesophageal Junction Adenocarcinoma

Interventions

DRUG: Retlirafusp Alfa
DRUG: Oxaliplatin
DRUG: Capecitabine
PROCEDURE: Radical Surgery

Sponsor

Tang-Du Hospital